Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1100220200190010001
Dementia and Neurocognitive Disorders
2020 Volume.19 No. 1 p.1 ~ p.18
Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Lee Hee-Yang

Ugay Daniella
Hong Seung-Pyo
Kim Young-Soo
Abstract
Alzheimer's disease (AD) is pathologically characterized by a long progressive phase of neuronal changes, including accumulation of extracellular amyloid-¥â (A¥â) and intracellular neurofibrillary tangles, before the onset of observable symptoms. Many efforts have been made to develop a blood-based diagnostic method for AD by incorporating A¥â and tau as plasma biomarkers. As blood tests have the advantages of being highly accessible and low cost, clinical implementation of AD blood tests would provide preventative screening to presymptomatic individuals, facilitating early identification of AD patients and, thus, treatment development in clinical research. However, the low concentration of AD biomarkers in the plasma has posed difficulties for accurate detection, hindering the development of a reliable blood test. In this review, we introduce three AD blood test technologies emerging in South Korea, which have distinctive methods of heightening detection sensitivity of specific plasma biomarkers. We discuss in detail the multimer detection system, the self-standard analysis of A¥â biomarkers quantified by interdigitated microelectrodes, and a biomarker ratio analysis comprising A¥â and tau.
KEYWORD
Alzheimer's Disease, Amyloid-beta Peptides, Biomarkers, Diagnostic Techniques and Procedures, Plasma, tau Proteins
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed